LOCUS CELL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.65 TWD | +3.86% |
|
+9.08% | +6.83% |
| May. 24 | Locus Cell Co., Ltd. Announces Board Changes | CI |
| May. 24 | Locus Cell Co., Ltd. Announces the Expiration of First Compensation Committee Members | CI |
| Sales 2022 | 0.6 19.48 | Sales 2023 | 0.41 13.18 | Capitalization | 6.3B 205B |
|---|---|---|---|---|---|
| Net income 2022 | -53M -1.72B | Net income 2023 | -96M -3.12B | EV / Sales 2022 | 9,042,435,000 x |
| Net cash position 2022 | 1.8B 58.58B | Net cash position 2023 | 1.63B 52.95B | EV / Sales 2023 | 11,499,236,453 x |
| P/E ratio 2022 |
-134
x | P/E ratio 2023 |
-65
x | Employees | 33 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.86% | ||
| 1 week | +9.08% | ||
| 1 month | +7.85% | ||
| 3 months | +14.65% | ||
| 6 months | +3.54% | ||
| Current year | +6.83% |
1 week
30.30
33.75
1 month
28.3033.75
Current year
22.2033.75
1 year
22.2045.50
3 years
22.2073.60
5 years
22.2073.60
10 years
22.2073.60
| Managers | Title | Age | Since |
|---|---|---|---|
Chun Wei Chen
DFI | Director of Finance/CFO | - | - |
Heng Yu Liu
CTO | Chief Tech/Sci/R&D Officer | - | 21-11-14 |
An Chih Teng
ADM | Chief Administrative Officer | - | 21-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hung Jen Yang
BRD | Director/Board Member | 55 | 21-05-30 |
Shih Chia Lin
BRD | Director/Board Member | - | 21-05-30 |
Hung Neng Ho
CHM | Chairman | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 33.65 | +3.86% | 658,913 |
| 24-05-30 | 32.4 | -2.56% | 571,359 |
| 24-05-29 | 33.25 | +8.31% | 1,064,791 |
| 24-05-28 | 30.7 | -0.65% | 186,900 |
| 24-05-27 | 30.9 | +0.16% | 222,611 |
End-of-day quote Taipei Exchange, May 30, 2024
More quotes
Locus Cell Co Ltd is a Taiwan-based company mainly engaged in the biotechnology and pharmaceutical business. The Company is currently expected to provide cell therapy contract manufacturing organization (CDMO) production and development services using a pilot Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) good manufacturing practices (GMP) facility, with related technologies for cell therapy products (expected to include tissue engineering related products, CAR-T, iPSCs, MSC and other cell therapy applications), process development and process scale-up, analytical method development and validation, clinical GMP manufacturing process for clinical trials, and stability testing.
| 1st Jan change | Capi. | |
|---|---|---|
| +6.83% | 207M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- 6891 Stock
